Начало・Списък с акции・Viking Therapeutics Inc

Viking Therapeutics Inc

Затворен

СекторЗдравеопазване

33.34 1.62

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

32.81

Максимум

Ключови измерители
By Trading Economics
Приходи	30M -128M
EPS	-1.1
Служители	65
EBITDA	30M -128M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+179.54% upside

Дивиденти
By Acuity
Следващи печалби	21.10.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-245M 3.8B
Предишно отваряне	31.72
Предишно затваряне	33.34

Настроения в новините

By Acuity

50%

156 / 340 Класиране в Healthcare

Viking Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2026 г., 22:51 ч. UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4.08.2026 г., 23:02 ч. UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3.08.2026 г., 23:06 ч. UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31.07.2026 г., 23:51 ч. UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30.07.2026 г., 23:56 ч. UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29.07.2026 г., 23:21 ч. UTC

Social Media

News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28.07.2026 г., 23:11 ч. UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27.07.2026 г., 23:56 ч. UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25.07.2026 г., 00:01 ч. UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24.07.2026 г., 21:01 ч. UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23.07.2026 г., 23:46 ч. UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22.07.2026 г., 23:36 ч. UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Сравнение с други в отрасъла

Ценова промяна

Viking Therapeutics Inc Прогноза

Ценова цел

By TipRanks

179.54% нагоре

12-месечна прогноза

Среден 92.08 USD 179.54%

Висок 114 USD

Нисък 70 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Viking Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Viking Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

156 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.